Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05486546 · ClinicalTrials.gov registry record · NA
Contoura With Phorcides Compared to Wavefront Optimized LASIK
A NA study of Myopia and Astigmatism, sponsored by Daniel Terveen.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 4
- Study locations
NCT05486546: Recruiting NA study of Myopia and Astigmatism, sponsored by Daniel Terveen.
NCT05486546 is a NA study of Myopia and Astigmatism that is actively recruiting participants, run by Daniel Terveen. The registered enrollment target is 120 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (55% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05486546, a NA study of Myopia and Astigmatism, is actively recruiting participants, sponsored by Daniel Terveen.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 4
- Study locations
Study Summary
Comparing post-operative visual acuity and patient reported satisfaction between Contoura with Phorcides and WaveLight Wavefront Optimized.
Primary Outcome
Percent of participants with monocular UDVA of 20/16 or better
Conditions Studied
Interventions
- PROCEDURE Contoura with Phorcides
- DEVICE WaveLight Wavefront Optimized
Study Locations (4)
Montana
- Vance Thompson Vison - Bozeman
Nebraska
- Vance Thompson Vision - Omaha
North Dakota
- Vance Thompson Vision - Fargo
South Dakota
- Vance Thompson Vision - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-08-15 |
| Est. Completion | 2023-12-01 |
| Phase | NA |
What NCT05486546 shows while recruiting
NCT05486546 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (55% lower).
The record links to 2 conditions, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Contoura with Phorcides is the first listed.
NCT05486546 reports a single indexed study location in Montana, Nebraska, North Dakota.
Frequently Asked Questions
What is clinical trial NCT05486546 about?
NCT05486546 is a clinical study titled "Contoura With Phorcides Compared to Wavefront Optimized LASIK". Comparing post-operative visual acuity and patient reported satisfaction between Contoura with Phorcides and WaveLight Wavefront Optimized.
What is the current status of trial NCT05486546?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2022-08-15. Estimated completion is 2023-12-01.
What conditions does trial NCT05486546 study?
This clinical trial studies the following conditions: Myopia, Astigmatism.
What interventions are being tested in trial NCT05486546?
The interventions under investigation include: Contoura with Phorcides (PROCEDURE), WaveLight Wavefront Optimized (DEVICE).
Who is sponsoring clinical trial NCT05486546?
This trial is sponsored by Daniel Terveen, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05486546 being conducted?
This trial has 4 study locations across Montana, Nebraska, North Dakota, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05486546's enrollment target sits among peer trials
120 32nd of 90 higher than 58 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI